Adaptive Biotechnologies to Offer $250M Convertible Notes, Plans Share Repurchase
ADPT sits 61% above its 52-week low of $9.9.
Summary
Adaptive Biotechnologies announced a proposed offering of $250 million in convertible senior notes due 2031, with an option for an additional $37.5 million. This follows the company's strong Q1 2026 financial results reported on May 5th, which showed 35% revenue growth and reduced net loss. The offering is a significant capital raise, representing about 9% of the company's market cap. While convertible notes carry potential for future equity dilution, the company plans to use up to $25 million of the proceeds for concurrent share repurchases and enter into capped call transactions to mitigate this. Proceeds will also repay the OrbiMed Purchase Agreement and fund general corporate purposes.
At the time of this announcement, ADPT was trading at $15.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $9.90 to $20.76. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.